Altai Protocol Library
Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions
New Reference: Rucaparib for Maintenance in Advanced Ovarian Cancer
The ATHENA-MONO study demonstrated significant improvement in progression-free survival with rucaparib as maintenance therapy for newly diagnosed advanced ovarian cancer. The hazar
New Indication: Trastuzumab Deruxtecan with Pertuzumab for First-Line Metastatic Her2-Positive Breast Cancer
Trastuzumab deruxtecan plus pertuzumab demonstrated a significantly lower risk of progression or death compared to the THP regimen as a first-line treatment for HER2-positive metas
New Indication: Neoadjuvant Trastuzumab Deruxtecan For High-Risk her2-Positive Breast Cancer
This phase 3 trial showed that T-DXd-THP significantly improved the pathological complete response rate compared with ddAC-THP in high-risk HER2-positive early breast cancer, with
New Reference: 3 vs 6 Cycles of Chemotherapy for Advanced Urothelial Carcinoma
The phase II DISCUS trial investigated the effectiveness of 3 versus 6 cycles of platinum-based chemotherapy followed by avelumab maintenance in advanced urothelial cancer patients
New Reference: Panitumumab for Ras/Raf WT Metastatic Colorectal Cancer After Anti-EGFR Therapy
The study evaluated sequencing of panitumumab and regorafenib in chemorefractory colorectal cancer, showing no difference in overall survival but superior response rates and diseas
New Drug: Ziftomenib for Relapsed/Refractory NPM1-Mutated AML
Ziftomenib monotherapy led to a complete remission rate of 22% with a median overall survival of 6.6 months among relapsed/refractory NPM1-mutated AML patients. It was well tolerat
New Drug: Izalontamab Brengitecan for Metastatic Nasopharyngeal Carcinoma
Izalontamab brengitecan significantly improved objective response rate and progression-free survival compared to chemotherapy in heavily pretreated nasopharyngeal carcinoma patient
New Protocol: Ivonescimab with Chemotherapy for Untreated Advanced Squamous NSCLC
The HARMONi-6 trial showed that ivonescimab combined with chemotherapy significantly improved progression-free survival compared to tislelizumab combined with chemotherapy. The tre
New Protocol: Inotuzumab Ozogamicin Then Blinatumomab for Older Adults with Ph-Negative ALL
Inotuzumab ozogamicin followed by blinatumomab without chemotherapy showed high remission and survival rates in older patients with Ph-negative B-cell ALL. The regimen achieved a C
Our Solutions
Articles
Computerized Chemotherapy Order Entry
Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …
Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.